» Articles » PMID: 28987176

Immune-mediated Disorders

Overview
Publisher Elsevier
Specialty Neurology
Date 2017 Oct 9
PMID 28987176
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Paraneoplastic and autoimmune encephalitis comprise a group of immune-mediated disorders that are associated with different immune effector mechanisms. Classic paraneoplastic neurologic syndromes are triggered by an antitumor immune response. The disease is considered to result from a T-cell response; in addition, patients harbour high titers of autoantibodies against intracellular antigens that are considered as epiphenomenon but are useful diagnostic markers. Neuropathology consists of T-cell-dominated inflammation, marked neuronal loss, and microglial activation with upregulation of HLA-DR. In the last decade, an increasing number of diseases associated with autoantibodies against neuronal surface antigens have been described. There is strong evidence that these autoantibodies are pathogenic and the associated syndromes are generally termed as antineuronal autoimmune encephalitis. Patients typically present with limbic, multifocal, or diffuse encephalitis and respond to immunotherapy. Neuropathologic descriptions are restricted to few biopsy and autopsy specimens and show mild inflammatory infiltrates and microglial activation, together with reduced expression of the respective target antigens, immunoglobulin deposits, and a variable degree of complement activation. Other putative autoimmune disorders of the central nervous system include, among others, Rasmussen encephalitis, chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS), acute cerebellitis, Susac syndrome, and Hashimoto encephalitis. While pathologic studies suggest an immune-mediated disease for Rasmussen encephalitis, CLIPPERS, acute cerebellitis, and Susac syndrome, neuropathologic descriptions of Hashimoto encephalitis are rare and the pathogenesis deserves further study.

Citing Articles

Intrathecal tocilizumab for immune-mediated central nervous system complication after haploidentical hematopoietic stem cell transplantation in children: Two case reports.

Gui R, Li Z, Wang J, Zu Y, Zhang B, Zhao J Heliyon. 2024; 10(22):e40356.

PMID: 39624308 PMC: 11609442. DOI: 10.1016/j.heliyon.2024.e40356.


Clinical and diagnostic characteristics of Hashimoto's encephalopathy: a single-center, retrospective study.

Lee J, Park S, Park K, Kang K, Lee W, Kim B Acta Neurol Belg. 2024; 124(6):1839-1846.

PMID: 38861245 PMC: 11614988. DOI: 10.1007/s13760-024-02520-1.


Neuroinflammation: 2021 update.

Lassmann H Free Neuropathol. 2023; 2.

PMID: 37284634 PMC: 10209849. DOI: 10.17879/freeneuropathology-2021-3166.


Multiple sclerosis: 2023 update.

Kuhlmann T, Antel J Free Neuropathol. 2023; 4.

PMID: 37283934 PMC: 10209995. DOI: 10.17879/freeneuropathology-2023-4675.


Targeting Underlying Inflammation in Carcinoma Is Essential for the Resolution of Depressiveness.

Borovcanin M, Vesic K, Arsenijevic D, Milojevic-Rakic M, Mijailovic N, Jovanovic I Cells. 2023; 12(5).

PMID: 36899845 PMC: 10000718. DOI: 10.3390/cells12050710.